University of Copenhagen
Total Page:16
File Type:pdf, Size:1020Kb
Artificial Intelligence and Early Detection of Pancreatic Cancer 2020 Summative Review Kenner, Barbara; Chari, Suresh T; Kelsen, David; Klimstra, David S; Pandol, Stephen J; Rosenthal, Michael; Rustgi, Anil K; Taylor, James A; Yala, Adam; Abul-Husn, Noura; Andersen, Dana K; Bernstein, David; Brunak, Søren; Canto, Marcia Irene; Eldar, Yonina C; Fishman, Elliot K; Fleshman, Julie; Go, Vay Liang W; Holt, Jane M; Field, Bruce; Goldberg, Ann; Hoos, William; Iacobuzio-Donahue, Christine; Li, Debiao; Lidgard, Graham; Maitra, Anirban; Matrisian, Lynn M; Poblete, Sung; Rothschild, Laura; Sander, Chris; Schwartz, Lawrence H; Shalit, Uri; Srivastava, Sudhir; Wolpin, Brian Published in: Pancreas DOI: 10.1097/MPA.0000000000001762 Publication date: 2021 Document version Publisher's PDF, also known as Version of record Document license: CC BY-NC-ND Citation for published version (APA): Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., Andersen, D. K., Bernstein, D., Brunak, S., Canto, M. I., Eldar, Y. C., Fishman, E. K., Fleshman, J., Go, V. L. W., Holt, J. M., ... Wolpin, B. (2021). Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Pancreas, 50(3), 251-279. https://doi.org/10.1097/MPA.0000000000001762 Download date: 27. sep.. 2021 CONFERENCE REPORT Artificial Intelligence and Early Detection of Pancreatic Cancer 2020 Summative Review Barbara Kenner, PhD,* Suresh T. Chari, MD,† David Kelsen, MD,‡ David S. Klimstra, MD,§ Stephen J. Pandol, MD,|| Michael Rosenthal, MD, PhD,¶ Anil K. Rustgi, MD,# James A. Taylor, MD,** 05/18/2021 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= by https://journals.lww.com/pancreasjournal from Downloaded Adam Yala, MEng,††‡‡ Noura Abul-Husn, MD, PhD,§§ Dana K. Andersen, MD, FACS,|||| David Bernstein, PhD,¶¶ Søren Brunak, PhD,## Marcia Irene Canto, MD, MHS,*** Yonina C. Eldar, PhD,††† Downloaded Elliot K. Fishman, MD,‡‡‡ Julie Fleshman, JD, MBA,§§§ Vay Liang W. Go, MD,|||||| Jane M. Holt, BA,¶¶¶ Bruce Field, BS,* Ann Goldberg, BA,* William Hoos, MBA,### Christine Iacobuzio-Donahue, MD, PhD,**** from Debiao Li, PhD,†††† Graham Lidgard, PhD,‡‡‡‡ Anirban Maitra, MBBS,§§§§ https://journals.lww.com/pancreasjournal Lynn M. Matrisian, PhD, MBA,§§§ Sung Poblete, RN, PhD,|||||||| Laura Rothschild, MBA,* Chris Sander, PhD,¶¶¶¶ Lawrence H. Schwartz, MD,#### Uri Shalit, PhD,***** Sudhir Srivastava, PhD, MPH, MS,††††† and Brian Wolpin, MD, MPH‡‡‡‡‡ Key Words: artificial intelligence, machine learning, pancreatic cancer, by Abstract: Despite considerable research efforts, pancreatic cancer is as- early detection BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= sociated with a dire prognosis and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly nonspecific. The premise of improved (Pancreas 2021;50: 251–279) survival through early detection is that more individuals will benefit from potentially curative treatment. Artificial intelligence (AI) methodology has emerged as a successful tool for risk stratification and identification ancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) in general health care. In response to the maturity of AI, Kenner Family Re- Pis associated with a dire prognosis and a 5-year survival rate search Fund conducted the 2020 AI and Early Detection of Pancreatic of only 10%.1 This statistic is somewhat misleading given that Cancer Virtual Summit (www.pdac-virtualsummit.org) in conjunction with 52% of the patients will develop metastatic disease, with a the American Pancreatic Association, with a focus on the potential of AI to resulting 2.9%, 5-year relative survival rate. However, for those advance early detection efforts in this disease. This comprehensive presum- patients with localized cancer where the tumor is confined to the mit article was prepared based on information provided by each of the in- primary site, the 5-year relative survival rate is 39.4%. It is esti- terdisciplinary participants on one of the 5 following topics: Progress, mated that in 2020, there will be 57,600 new cases of PDAC Problems, and Prospects for Early Detection; AI and Machine Learning; and an estimated 47,050 will die of this disease.1 AI and Pancreatic Cancer—Current Efforts; Collaborative Opportunities; Early symptoms of PDAC are mostly nonspecific, with both and Moving Forward—Reflections from Government, Industry, and Advo- intrinsic and extrinsic risk factors believed to be involved.2 The cacy. The outcome from the robust Summit conversations, to be presented premise of improved survival through early detection is that more in a future white paper, indicate that significant progress must be the result individuals will benefit from potentially curative treatment. Be- of strategic collaboration among investigators and institutions from multi- cause symptoms typically occur late in the course of the disease, de- disciplinary backgrounds, supported by committed funders. tection of early/resectable pancreatic cancer will possibly require From the *Kenner Family Research Fund, New York, NY; †Department of Gas- ‡‡‡‡Exact Sciences, Madison, WI; §§§§Department of Pathology, The Uni- troenterology, Hepatology and Nutrition, The University of Texas MD Anderson versity of Texas MD Anderson Cancer Center, Houston, TX; ||||||||Stand Up Cancer Center, Houston, TX; ‡Edward S. Gordon Chair in Medical Oncology To Cancer, Los Angeles, CA; ¶¶¶¶Sander Lab, Harvard Medical School, and §Department of Pathology, Memorial Sloan Kettering Cancer Center, New Boston, MA; ####Department of Radiology, NewYork-Presbyterian York, NY; ||Basic and Translational Pancreas Research Program, Department Hospital/Columbia University Irving Medical Center, New York, NY; of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; ¶Department of *****Faculty of Industrial Engineering and Management, Technion—Israel on Radiology, Dana-Farber Cancer Institute, Boston, MA; #Division of Diges- Institute of Technology, Haifa, Israel; †††††Division of Cancer Prevention, Na- 05/18/2021 tive and Liver Diseases, Department of Medicine, NewYork-Presbyterian/ tional Cancer Institute, Bethesda, MD; ‡‡‡‡‡Gastrointestinal Cancer Center, Columbia University Irving Medical Center, New York, NY; **Google Dana-Farber Cancer Institute, Boston, MA. Health, Seattle, WA; ††Department of Electrical Engineering and Com- Address correspondence to: Barbara Kenner, PhD, Kenner Family Research puter Science and ‡‡Jameel Clinic, Massachusetts Institute of Technology, Fund, 1202 Lexington Avenue, No. 104, New York, NY 10028 Cambridge, MA; §§Division of Genomic Medicine, Department of Medi- (e‐mail: [email protected]). cine, Icahn School of Medicine, Mount Sinai, New York, NY; ||||Division S.T.C., D.K., D.S.K., S.P., M.R., A.K.R., J.A.T., and A.Y. are section leads. of Digestive Diseases and Nutrition, National Institute of Diabetes and Di- Other authors are listed in alphabetical order. gestive and Kidney Diseases, Bethesda, MD; ¶¶Stand Up To Cancer, New This article was prepared for the AI and Early Detection of Pancreatic York, NY; ##Novo Nordisk Foundation Center for Protein Research, Uni- Cancer 2020 Virtual Summit through the support of Kenner Family versity of Copenhagen, Copenhagen, Denmark; ***Division of Gastroen- Research Fund. terology, Johns Hopkins University School of Medicine, Baltimore, MD; The authors declare no conflict of interest. S.T.C., B. F., V.L.W.G., W.H., and †††Department of Math and Computer Science, Weizmann Institute of Sci- D.S.K. are Kenner Family Research Fund scientific advisors. A.G., B.K., ence, Rehovot, Israel; ‡‡‡Department of Radiology and Radiological Sci- and L.R. are Kenner Family Research Fund board members. ence, Johns Hopkins Medicine, Baltimore, MD; §§§Pancreatic Cancer Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. Action Network, Manhattan Beach; ||||||UCLA Center for Excellence in This is an open-access article distributed under the terms of the Creative Pancreatic Diseases, University of California, Los Angeles, Los Angeles, Commons Attribution-Non Commercial-No Derivatives License 4.0 CA; ¶¶¶National Pancreas Foundation, Bethesda, MD; ###1440 Founda- (CCBY-NC-ND), where it is permissible to download and share the work tion, Chapel Hill, NC; ****David M. Rubenstein Center for Pancreatic Cancer provided it is properly cited. The work cannot be changed in any way or Research, Memorial Sloan Kettering Cancer Center, New York, NY; ††††Bio- used commercially without permission from the journal. medical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; DOI: 10.1097/MPA.0000000000001762 Pancreas • Volume 50, Number 3, March 2021 www.pancreasjournal.com 251 Kenner et al Pancreas • Volume 50, Number 3, March 2021 screening asymptomatic subjects. Although it remains cost-prohibitive period as a tool for risk stratification and identification in general and challenging with current technology to screen the general health care; hence, plans were initiated for the 2020 AI and Early population for PDAC, the ability to define high-risk groups with Detection of Pancreatic Cancer Virtual Summit (www.pdac- an increased likelihood of harboring such lesions may lead to ear- virtualsummit.org). Participants were selected given their areas lier interception and improved survival. of expertise, knowledge, and/or commitment to the